Full text is available at the source.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study (SWITCH‐SEMA 1 study)
Better blood sugar control and treatment satisfaction after switching from liraglutide or dulaglutide to injected semaglutide in type 2 diabetes patients
AI simplified
Abstract
In a study of 110 patients, switching to once-weekly semaglutide significantly reduced glycated haemoglobin levels.
- Patients switching from liraglutide showed a reduction in glycated haemoglobin from 7.9% to 7.3%.
- Those switching from dulaglutide experienced a decrease in glycated haemoglobin from 7.8% to 7.1%.
- Diabetes Treatment Satisfaction Questionnaire scores improved significantly in both groups after switching to semaglutide.
- The increase in treatment satisfaction was +8.3 for the liraglutide group and +3.5 for the dulaglutide group.
- Switching from dulaglutide resulted in greater reductions in body weight and better metabolic outcomes.
AI simplified